Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198-6270, USA.
Arthritis Res Ther. 2011;13(5):R168. doi: 10.1186/ar3491. Epub 2011 Oct 18.
Minocycline and doxycycline are safe and moderately effective disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of early, DMARD-naïve rheumatoid arthritis (RA), although little is known about their use outside clinical trials. We characterize the use of minocycline and doxycycline in community-dwelling RA patients by examining associated prescribing patterns, patient-level determinants of use, and side-effect profiles.
We studied 15,716 patients with RA observed between 1998 and 2009 while participating in a long-term US observational study.
Minocycline or doxycycline was prescribed by 18% of rheumatologists (interquartile range one to two patients per physician) to 9% of RA patients. Significant differences between minocycline-treated and doxycycline-treated patients and nontreated patients included age (58.4 years vs. 59.8 years), RA duration (14.8 years vs. 13.7 years), Caucasian race (93.7% vs. 89.7%), lifetime DMARDs and biologics (3.3 vs. 2.5), prednisone use (40.1% vs. 35.3%), and Medical Outcomes Study 36-Item Short Form Survey physical component summary score (35.0 vs. 36.4). In multivariable Cox regression, patients initiating minocycline or doxycycline had increased disease activity, more comorbidities, and a greater number of prior nonbiologic DMARDs. Side effects were reported by 17.8% of minocycline users and 11.8% of doxycycline users. Skin complaints accounted for 54% of minocycline patient-reported side effects. The most commonly effected organ systems for doxycycline were gastrointestinal (35.4%) and skin (33.7%). Approximately 75% of side effects were of mild or moderate severity.
Rheumatologists have not embraced minocycline or doxycycline as primary treatment options for RA and reserve their use primarily in patients with long-standing, refractory disease. These drugs are generally well tolerated, with skin complaints, nausea, and dizziness being the most common patient-reported side effects.
米诺环素和多西环素是安全且中度有效的治疗早期、初治的类风湿关节炎(DMARD -naive RA)的疾病修饰抗风湿药物(DMARDs),尽管关于它们在临床试验之外的使用知之甚少。我们通过检查相关的处方模式、患者使用的决定因素以及副作用特征来描述社区居住的 RA 患者中米诺环素和多西环素的使用情况。
我们研究了 1998 年至 2009 年间参与一项长期美国观察性研究的 15716 名 RA 患者。
18%的风湿病学家(医生每例患者开具一至两名患者)为 9%的 RA 患者开具了米诺环素或多西环素。米诺环素治疗组和多西环素治疗组与未治疗组患者之间存在显著差异,包括年龄(58.4 岁比 59.8 岁)、RA 病程(14.8 年比 13.7 年)、白种人(93.7%比 89.7%)、终身 DMARD 和生物制剂(3.3 比 2.5)、泼尼松使用(40.1%比 35.3%)和医疗结局研究 36 项简明健康调查量表躯体成分总分(35.0 比 36.4)。多变量 Cox 回归分析显示,开始使用米诺环素或多西环素的患者疾病活动度更高、合并症更多、且先前使用的非生物 DMARD 数量更多。17.8%的米诺环素使用者和 11.8%的多西环素使用者报告了副作用。米诺环素患者报告的副作用中,皮肤问题占 54%。多西环素最常影响的器官系统是胃肠道(35.4%)和皮肤(33.7%)。大约 75%的副作用为轻度或中度严重程度。
风湿病学家并未将米诺环素或多西环素作为 RA 的主要治疗选择,而是主要将其保留用于患有长期、难治性疾病的患者。这些药物通常耐受性良好,最常见的患者报告的副作用是皮肤问题、恶心和头晕。